In our study, we found that in the elderly with T2DM, those on metformin (regardless of whether it was metformin alone or combined with other oral hypoglycemic drugs and insulin) manifested a reduced risk for sarcopenia relative to those patients on no medication. This evidence concerns the gene INS and type 2 diabetes mellitus.